Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based studyKuniko Sunami, Takashi Kohno, Eisaku Furukawa et al.|Cancer Science|2019Cited by 375
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01Toshio Shimizu, Rebecca S. Heist, Jacob Sands et al.|Journal of Clinical Oncology|2023Cited by 168
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapyYoshio Nakamura, Naoya Yamazaki, Shigehisa Kitano et al.|Oncotarget|2016Cited by 160
First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid TumorsToshio Shimizu, Noboru Yamamoto, Yutaka Fujiwara et al.|Clinical Cancer Research|2021Cited by 97
Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I studyShunji Takahashi, Noboru Yamamoto, Yutaka Fujiwara et al.|Cancer Science|2021Cited by 72